ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Biotechnology

Fujifilm's Komori says health care can double to $10bn business

CEO sees M&A boosting scale while mainstay copier operations slow down

Fujifilm Holdings CEO Shigetaka Komori sees regenerative medicine making strong contributions to earnings in several years. (Photo by Yasunori Okamura)

TOKYO -- Fujifilm Holdings aims to roughly double sales in its health care business to crack 1 trillion yen ($9.24 billion) in the next several years, seeking to build a new reliable income driver as its mainstay copier business stagnates.

The Tokyo-based company wants to win more orders to develop biopharmaceuticals on a contract basis while also focusing on medical equipment and information systems for hospitals, Chairman and CEO Shigetaka Komori said in an interview with Nikkei.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more